Dr. Annie Massart and fellow hospitalists offer pros, cons, and tips for bedside rounding

**IN THE LITERATURE**

**University of New Mexico**

Drs. Miller, Kaur, Sheikh, Subramany, Richardson, and Imber’s lit reviews

**CLINICAL**

**Cavitary lung lesion update**

Drs. Pizanis, Wurzburger, Rendón, and Dean update a most-read article

**IN THE NEXT ISSUE**

Hospitalist/military vet, PHM recaps, and EHR
Where dysbiosis once left the gut microbiome in ruin,

RISE ABOVE RECURRENT
C. DIFFICILE INFECTION

and restore hope with REBYOTA®

The first and only single-dose microbiota-based live biotherapeutic approved to prevent recurrence of C. difficile infection starting at first recurrence.1,2,a

INDICATION
REBYOTA (fecal microbiota, live - jslm) is indicated for the prevention of recurrence of Clostridioides difficile infection (CDI) in individuals 18 years of age and older, following antibiotic treatment for recurrent CDI.

Limitation of Use
REBYOTA is not indicated for treatment of CDI.

IMPORTANT SAFETY INFORMATION

Contraindications
Do not administer REBYOTA to individuals with a history of a severe allergic reaction (eg, anaphylaxis) to any of the known product components.

Warnings and Precautions

Transmissible infectious agents
Because REBYOTA is manufactured from human fecal matter, it may carry a risk of transmitting infectious agents. Any infection suspected by a physician possibly to have been transmitted by this product should be reported by the physician or other healthcare provider to Ferring Pharmaceuticals Inc.

Management of acute allergic reactions
Appropriate medical treatment must be immediately available in the event an acute anaphylactic reaction occurs following administration of REBYOTA.

Potential presence of food allergens
REBYOTA is manufactured from human fecal material and may contain food allergens. The potential for REBYOTA to cause adverse reactions due to food allergens is unknown.

Adverse Reactions
The most commonly reported (≥3%) adverse reactions occurring in adults following a single dose of REBYOTA were abdominal pain (8.9%), diarrhea (7.2%), abdominal distention (3.9%), flatulence (3.3%), and nausea (3.3%).

Use in Specific Populations

Pediatric Use
Safety and efficacy of REBYOTA in patients below 18 years of age have not been established.

Geriatric Use
Of the 978 adults who received REBYOTA, 48.8% were 65 years of age and over (n=477), and 25.7% were 75 years of age and over (n=251). Data from clinical studies of REBYOTA are not sufficient to determine if adults 65 years of age and older respond differently than younger adults.

You are encouraged to report negative side effects of prescription drugs to FDA. Visit www.FDA.gov/medwatch, or call 1-800-332-1088.

Please see Brief Summary on next page and full Prescribing Information at www.REBYOTAHCP.com.

References
RISE ABOVE RECURRENT

Where dysbiosis once left the gut microbiome in ruin, REBYOTA and restore hope with...

In the pivotal phase 3 trial, 32.8% of patients were treated at first recurrence of CDI following antibiotic treatment of CDI. 1 infection starting at first recurrence. 1,2,a

REBYOTA to cause adverse reactions due to food and may contain food allergens. The potential for REBYOTA to cause adverse reactions due to food allergens is unknown. 

Potential presence of food allergens: REBYOTA is manufactured from human fecal matter and may contain food allergens. The potential for REBYOTA to cause adverse reactions due to food allergens is unknown.

ADVERSE REACTIONS

The most commonly reported (≥ 3%) adverse reactions occurring in adults following a single dose of REBYOTA were abdominal pain, (8.9%), diarrhea (7.2%), abdominal distention (3.9%), flatulence (3.3%), and nausea (3.3%).

Clinical Trials Experience: The safety of REBYOTA was evaluated in 2 randomized, double-blind clinical studies (Study 1 and Study 2) and 3 open-label clinical studies conducted in the United States and Canada. A total of 978 adults 18 years of age and older with a history of 1 or more recurrences of Clostridioides difficile (CDI) infection and whose symptoms were controlled 24 – 72 hours post-antibiotic treatment were enrolled and received 1 or more doses of REBYOTA; 595 of whom received a single dose of REBYOTA.

Adverse Reactions: Across the 5 clinical studies, participants recorded solicited adverse events in a diary for the first 7 days after each dose of REBYOTA or placebo. Participants were monitored for all other adverse events by queries during scheduled visits, with duration of follow-up ranging from 6 to 24 months after the last dose. In an analysis of solicited and unsolicited adverse events reported in Study 1, the most common adverse reactions (defined as adverse events assessed as definitely, possibly, or probably related to Investigational Product by the investigator) reported by ≥3% of REBYOTA recipients, and at a rate greater than that reported by placebo recipients, were abdominal pain, (8.9%), diarrhea (7.2%), abdominal distention (3.9%), flatulence (3.3%), and nausea (3.3%). Most adverse reactions occurred during the first 2 weeks after treatment. After this, the proportion of patients with adverse reactions declined in subsequent 2-week intervals. Beyond 2 weeks after treatment only a few single adverse reactions were reported. Most adverse drug reactions were mild to moderate in severity. No life-threatening adverse reaction was reported.

Serious Adverse Reactions - In a pooled analysis of the 5 clinical studies, 10.1% (60/595) of REBYOTA recipients (1 dose only) and 7.2% (6/83) of placebo recipients reported a serious adverse event within 6 months post last dose of investigational product. None of these events were considered related to the investigational product.

USE IN SPECIFIC POPULATIONS

Pregnancy: REBYOTA is not absorbed systemically following rectal administration, and maternal use is not expected to result in fetal exposure to the drug.

Lactation: REBYOTA is not absorbed systemically by the mother following rectal administration, and breastfeeding is not expected to result in exposure of the child to REBYOTA.

Pediatric Use: Safety and effectiveness of REBYOTA in individuals younger than 18 years of age have not been established.

Geriatric Use: Of the 978 adults who received REBYOTA, 48.8% were 65 years of age and over (n=477), and 25.7% were 75 years of age and over (n=251). Data from clinical studies of REBYOTA are not sufficient to determine if adults 65 years of age and older respond differently than younger adults.

For more information, visit www.REBYOTAHCP.com

You are encouraged to report negative side effects of prescription drugs to FDA. Visit www.FDA.gov/medwatch, or call 1-800-332-1088.

Manufactured for Ferring Pharmaceuticals by Rebiotix, Inc. Roseville, MN 55113

FERRING PHARMACEUTICALS

US License No. 2112
9009000002
Rx Only

Ferring, the Ferring Pharmaceuticals logo and REBYOTA are registered trademarks of Ferring B.V. ©2023 Ferring B.V.

This brief summary is based on full Rebyota Prescribing Information which can be found at www.RebyotaHCP.com

US-REB-2200277-V2
Case

A 64-year-old woman with a history of heart failure with reduced ejection fraction was admitted to the hospital with orthopnea and dyspnea on exertion for one week. You admitted her to the hospital for intravenous (IV) diuresis and you see her now on day three of her admission. She is diuretic adhering equally on IV Lasix 40 mg twice a day, but after examination, you feel like she needs another one to two days of IV diuretics. You order another basic metabolic panel to monitor her serum creatinine. You review her basic metabolic panel from the morning labs, speak to the patient’s daughter, and get some more history about the reason for this exacerbation.

Tip

Always look at the medical decision making table when billing. A chronic illness that needs hospital admission for exacerbation is usually looked upon as a severe exacerbation, and IV diuretics are common medications that need intensive monitoring of labs for toxicity.

Dr. Mehta is the medical director and an assistant professor of medicine at the University of Cincinnati Medical Center in Cincinnati.

Q: What level of billing does this qualify for?

A: This would qualify for level-3 (99233) billing. She would qualify for severe exacerbation of chronic illness by virtue of her being hospitalized (high level in complexity of problem addressed) and drug therapy needing intensive monitoring of labs for toxicity (high level for risk of complication). Even though the complexity of the data reviewed is moderate, she achieved high-level MDM, or medical decision making, in two out of three elements.

Get Published!

If you’re an SHM member interested in contributing to The Hospitalist, there are lots of opportunities. We publish articles about the news, trends, and issues that affect hospital medicine. Topics include everything from clinical and practice management to quality, career, leadership, pediatrics, and more.

And, if you want to express yourself creatively, there’s HM Voices, our online area showcasing your writing, creative writing, or poetry, creative writing, or creative. Voicesto, our online area showcasing yourself creatively, there’s HM practice management to quality, career, everything from clinical and prac-

HF and Physician Underbilling—Two Common Conditions

By Arunab Mehta, MD, MEd

Coding Corner, a new section that will appear periodically in The Hospitalist, features common coding and/or billing issues hospitalists regularly face. If you have suggestions for upcoming coding issues you’d like addressed, email us at lcasinger@wiley.com.

Q: What level of billing does this qualify for?

A: This would qualify for level-3 (99233) billing. She would qualify for severe exacerbation of chronic illness by virtue of her being hospitalized (high level in complexity of problem addressed) and drug therapy needing intensive monitoring of labs for toxicity (high level for risk of complication). Even though the complexity of the data reviewed is moderate, she achieved high-level MDM, or medical decision making, in two out of three elements.

Published in The Hospitalist, October 2023, Vol. 27, No. 10

The Hospitalist

SHM’s Diversity and Inclusion Statement

Hospitalists are charged with treating individuals at their most vulnerable moments, when being respected as a whole person is crucial to advancing patients’ healing and wellness. Within our workforce, diversity is a strength in all its forms, which helps us learn about the human experience, grow as leaders, and ultimately create a more equitable environment for all regardless of age, race, religion, national origin, gender identity, sexual orientation, socioeconomic status, appearance, or ability. To this end, the Society of Hospital Medicine will work to eliminate health disparities for our patients and foster inclusive and equitable cultures across our care teams and institutions with the goal of moving medicine and humanity forward.

Information for Subscribers

Print subscriptions are free for members of the Society of Hospital Medicine. Free access is also available online at thehospitalist.org. If you are an SHM member and have a subscription inquiry, contact 800-843-3360 or email customerservice@hospitalmedicine.org. If you are not an SHM member, please receive The Hospitalist, contact Wiley Periodicals LLC at 800-835-6770 (U.S. only) or email us at shm@wiley.com.

The Hospitalist is the official newspaper of the Society of Hospital Medicine, reporting on issues and trends in hospital medicine. The Hospitalist reaches more than 35,000 hospitalists, physician assistants, nurse practitioners, medical residents, and health care administrators interested in the practice and business of hospital medicine.

The Hospitalist (ISSN 1533-8015) is published monthly on behalf of the Society of Hospital Medicine by Wiley Periodicals LLC, 111 River Street, Hoboken, NJ 07030-5774. Postmaster: Send all address changes to The Hospitalist Wiley Periodicals LLC, c/o The Sheridan Press, PO Box 461, Hanover, PA, 17331. Printed in the United States by Sheridan of Ohio, Bremen, OH. Copyright © 2023 Society of Hospital Medicine. All rights reserved. No part of this publication may be reproduced, stored, or transmitted in any form or by any means and without the prior permission in writing from the copyright holder.

All materials published, including but not limited to original research, clinical notes, editorials, reviews, reports, letters, and book reviews, represent the opinions and views of the authors, and do not reflect any official policy or medical opinion of the institutions with which the authors are affiliated, the Society of Hospital Medicine, or of the publisher unless this is clearly specified. Materials published here are intended to further general scientific research, understanding, and discussion only and are not intended and should not be relied upon as recommending or promoting a specific method, diagnosis, or treatment by physicians for any particular patient. While the editors, society, and publisher believe that drug selections and dosages and the specifications and usage of equipment and devices as set forth herein are in accord with current recommendations and practice at the time of publication, they accept no liability for any errors or omissions, and make no warranty, express or implied, with respect to material contained herein. Publication of an advertisement or other discussions of products in this publication should not be construed as an endorsement of the products or the manufacturers’ claims. Readers are encouraged to contact the manufacturers with any questions about the features or limitations of the products mentioned.

The Society of Hospital Medicine is an independent professional organization of medical and scientific society that does not guarantee, warrant, or endorse any commercial products in medicine.
IN THIS ISSUE

1. Direct oral challenge is non-inferior to skin testing in low-risk penicillin allergy patients
   CLINICAL QUESTION: Is there an alternative to penicillin skin testing for low-risk penicillin allergies?
   BACKGROUND: While approximately 10% of the population report penicillin allergies, studies indicate that more than 95% of these individuals will have negative allergy testing and can tolerate penicillin. The current gold standard for relabeling a penicillin allergy involves skin testing followed by direct oral challenge. However, specialized allergy skin testing is not universally accessible, and can be labor-intensive and costly. Moreover, skin testing alone doesn’t conclusively demonstrate penicillin tolerance.
   STUDY DESIGN: Multicenter, open-label, randomized, controlled trial
   SETTING: Six large academic centers in three countries
   SYNOPSIS: 382 outpatient adults labeled with a reported penicillin allergy were assessed using the PEN-FAST scoring system. Those with a PEN-FAST score of less than 3 and no history of anaphylaxis were eligible. Participants were randomized to either intradermal testing followed by direct oral challenge or direct oral challenge alone. The primary outcome showed one patient in each intervention group experienced major bleeding risk without increasing ischemic risk after complex percutaneous coronary intervention.

2. Deprescribing medications among older adults from the end of hospitalization through post-acute care
   CLINICAL QUESTION: Can inpatient deprescribing interventions upon post-acute care facility discharge reduce the total medication burden?
   BACKGROUND: Polypharmacy remains a common concern in elderly patients due to associated adverse health outcomes. While deprescribing can be an important therapeutic intervention, it is usually practiced in primary care settings. There is underutilization of deprescribing in inpatient settings due to limited data and unclear information on the safety and effectiveness of deprescribing.
   STUDY DESIGN: Randomized controlled trial, May 2016 to October 2020
   SETTING: Vanderbilt University Medical Center, Nashville, Tenn.

3. Weighing benefits and risks of indefinite anticoagulation in first unprovoked VTE
   CLINICAL QUESTION: Is indefinite anticoagulation beneficial for patients with a first unprovoked venous thromboembolism (VTE) after initial treatment?
   BACKGROUND: VTE is a chronic, recurrent condition with significant health care costs. While guidelines recommend indefinite anticoagulation for a first unprovoked VTE, the balance between benefits and harms remains debated.
   STUDY DESIGN: Markov modeling study
   SETTING: Canadian health care public payer perspective
   SYNOPSIS: In a hypothetical cohort of 1,000 patients aged 55 years with a first unprovoked VTE, indefinite anticoagulation using direct oral anticoagulants was assessed. The results showed that while indefinite anticoagulation prevented 368 recurrent VTE events, including 14 fatal pulmonary emboli, it also led to 114 major

By Justin Miller, MD, FACP

By Harpreet Kaur, MD

By Abu Baker Sheikh, MD
bleeding events, with 30 intracranial hemorrhages and 11 bleeding-related deaths. The intervention cost an additional CAD $16,014 per person without increasing quality-adjusted life-years. The study's outcomes were particularly sensitive to the case-fatality rate of major bleeding and the annual risk for major bleeding during extended anticoagulation. The study's generalizability is limited by its focus on a specific population of patients (55-year-olds with a first unprovoked VTE) and its use of a Markov modeling approach. Hospitalists should engage patients in shared decision-making to determine the optimal duration of anticoagulation for patients with a first unprovoked VTE, carefully weighing the potential risks and benefits of indefinite anticoagulation.

**BOTTOM LINE:** Indefinite anticoagulation for the first unprovoked VTE presents a complex benefit-harm tradeoff. Shared decision-making, incorporating individual patient preferences, is crucial when considering treatment duration for unprovoked VTE.


---

**5** Pitavastatin and cardiovascular disease prevention in HIV patients

**CLINICAL QUESTION:** Does pitavastatin reduce the risk of cardiovascular disease in human immunodeficiency virus (HIV)-infected individuals?

**BACKGROUND:** Individuals with HIV infection have up to twice the risk of atherosclerotic cardiovascular disease compared to the general population. While statins are known to lower low-density lipoprotein cholesterol and have beneficial effects on inflammatory and immune pathways, their efficacy in primary prevention of cardiovascular events in HIV-infected patients is not well-established.

**STUDY DESIGN:** Phase 3 randomized trial

**SETTING:** Multi-center trial across 12 countries

**SYNOPSIS:** In this study of 7,769 virally suppressed HIV-infected individuals (median age 50), the efficacy of pitavastatin calcium (4 mg daily) was compared to a placebo in preventing major cardiovascular events. Over a median follow-up of 5.1 years, the pitavastatin group exhibited a reduced event rate of 4.81 per 1000 person-years, compared to the placebo group's 7.32. This translated to a hazard ratio of 0.65. However, the pitavastatin group reported increased muscle-related symptoms and a higher incidence of diabetes mellitus. The study's limitations include its relatively short duration, focus on a healthier HIV cohort, and lack of comparison with other statins.

**BOTTOM LINE:** Pitavastatin effectively prevents cardiovascular events in individuals with well-controlled HIV and a low-to-moderate cardiovascular disease risk, while maintaining a favorable tolerability profile.


---

**6** No difference between liberal versus strict perioperative BP management in non-cardiac surgery

**CLINICAL QUESTION:** In patients on antihypertensive medications (AHMs) such as angiotensin-converting enzyme inhibitors (ACE-Is) or angiotensin receptor blockers (ARBs) undergoing inpatient non-cardiac surgery, what blood pressure (BP) management strategy reduces the risk of major vascular complications?

**BACKGROUND:** Perioperatively, both hypertension and hypotension can lead to vascular complications after non-cardiac surgery. There is a lack of large robust trials that inform how AHMs should be managed; there is conflicting data regarding what the minimal intraoperative mean arterial pressure should be to reduce complications.

**STUDY DESIGN:** Randomized controlled trial comparing two perioperative BP management strategies

**SETTING:** 110 hospitals across 22 countries, from July 2018 to July 2021

**SYNOPSIS:** Using the measure accurately, act rapidly, and partner with patients (MAP) measurement techniques, 7,490 patients with vascular risk factors and taking at least one AHM were randomized to either a hypertension-avoidance strategy (step-wise AHM addition for SBP >130 mmHg on days 0-2 after surgery, avoidance of ACE-1 and ARBs on night before and days 0-3 after surgery; intraoperative MAP target >80mm Hg), or a hypertension-avoidance strategy (continuation of all chronic AHMs before and after surgery, intraoperative MAP target 60 mmHg). The mean age was 70 years, patients took a mean of two AHMs with a majority taking ACE-1 or ARBs and/or beta-blockers. The primary outcome, a composite of vascular death, non-fatal myocardial infarction, stroke, and cardiac arrest at 30 days, occurred in 13.9% of the hypertension-avoidance group and in 14% of the hypertension-avoidance group. Despite more significant hypertensive episodes in the hypertension-avoidance arm, this did not translate to higher major vascular complications. Limitations of the study include suboptimal adherence to treatment strategies and short-term 30-day follow-up.

**BOTTOM LINE:** For inpatient non-cardiac surgeries, there is no difference in major vascular complication risk between hypertension- or hypertension-avoidance-avoidance strategies, regardless of withholding ACE-1 or ARBs.


---

**7** Intensive blood pressure control with PO or IV harmful in hospitalized older adults

**CLINICAL QUESTION:** How do clinical outcomes compare between patients with asymptomatic hypertension treated intensively versus not while hospitalized?

**BACKGROUND:** While the long-term cardiovascular effects of untreated hypertension are clear, the short-term in-hospital consequences of hypertension remain uncertain. Previous studies have indicated that lowering blood pressure in hospital can lead to hypotension and acute kidney injury (AKI).

**STUDY DESIGN:** Retrospective observational cohort study

---
**METHODS:** Retrospective study of 4,485 patients with suspected sepsis identified in the emergency department of a Veterans Affairs Hospital from March 2007 to March 2010. Outcomes of interest included septic shock, in-hospital survival, and mortality.

**RESULTS:** Among patients who presented with suspected sepsis, those who received antibiotics within six hours had a 74% lower risk of septic shock and an 85% lower risk of death compared to those who received antibiotics after six hours. The results were consistent across various subgroups, including patients with diabetes, septic shock, and severe sepsis.

**CONCLUSIONS:** Early antibiotic administration is associated with improved outcomes in patients with suspected sepsis. These findings highlight the importance of prompt antibiotic administration in reducing the risk of septic shock and mortality. Early intervention can significantly improve patient outcomes and should be a priority in the management of sepsis.

**Risks and Limitations:** While these findings are promising, they are observational and do not establish causality. The findings may not be generalizable to all populations, and further research is needed to confirm these results and explore potential mechanisms.

---

**Become Part of SHM’s 2024 Class of Fellows and Senior Fellows**

**My SHM** designation allowed me to connect with other hospitalists and gave me national recognition among my peers. Ultimately, this led to growing leadership roles both at SHM and at my home hospital.

Dr. Imber is an assistant professor in the department of internal medicine, division of hospital medicine, and director of the internal medicine simulation education and hospitalist procedural certification at the University of New Mexico, Albuquerque, N.M.

---

**Delayed antibiotics in suspected sepsis increase shock risk and mortality**

**CLINICAL QUESTION:** Does the time to first antibiotics affect the risk of progression to septic shock?

**BACKGROUND:** Surviving Sepsis Campaign emphasized early infection recognition and antibiotic administration to reduce sepsis-related morbidity and mortality. Delayed antibiotic administration can lead to septic shock and related mortality. The Infectious Diseases Society of America now advocates for a tailored approach to antibiotic use based on risk/benefit balance. This study evaluated the risk of progression to shock and subsequent mortality in patients not yet diagnosed with sepsis.

**STUDY DESIGN:** Retrospective cohort study
For patients hospitalized with COVID-19,¹

HELP REDUCE DISEASE PROGRESSION AND SHORTEN RECOVERY TIME¹,²

INDICATION
VEKLURY is indicated for the treatment of COVID-19 in adults and pediatric patients (≥28 days old and weighing ≥3 kg), who are:
• Hospitalized, or
• Not hospitalized, have mild-to-moderate COVID-19, and are at high risk for progression to severe COVID-19, including hospitalization or death.

IMPORTANT SAFETY INFORMATION

Contraindication
• VEKLURY is contraindicated in patients with a history of clinically significant hypersensitivity reactions to VEKLURY or any of its components.

Warnings and precautions
• Hypersensitivity, including infusion-related and anaphylactic reactions: Hypersensitivity, including infusion-related and anaphylactic reactions, has been observed during and following administration of VEKLURY; most reactions occurred within 1 hour. Monitor patients during infusion and observe for at least 1 hour after infusion is complete for signs and symptoms of hypersensitivity as clinically appropriate. Symptoms may include hypotension, hypertension, tachycardia, bradycardia, hypoxia, fever, dyspnea, wheezing, angioedema, rash, nausea, diaphoresis, and shivering. Slower infusion rates (maximum infusion time of up to 120 minutes) can potentially prevent these reactions. If a severe infusion-related hypersensitivity reaction occurs, immediately discontinue VEKLURY and initiate appropriate treatment (see Contraindications).

• Increased risk of transaminase elevations: Transaminase elevations have been observed in healthy volunteers and in patients with COVID-19 who received VEKLURY; these elevations have also been reported as a clinical feature of COVID-19. Perform hepatic laboratory testing prior to initiating VEKLURY and monitor regularly during treatment. Transaminase elevations have been observed in healthy volunteers and in patients with COVID-19 who received VEKLURY, most occurring within 1 hour of the start of VEKLURY infusion. Transaminase elevations have also been reported as a clinical feature of COVID-19. Testing prior to and during treatment: Perform hepatic laboratory and prothrombin time testing prior to initiating VEKLURY treatment. If transaminase elevations occur, continue to monitor hepatic laboratory values. Testing should continue until transaminases return to baseline or normal levels. Monitor prothrombin time as clinically appropriate.

• Risk of reduced antiviral activity when coadministered with chloroquine or hydroxychloroquine: Coadministration of VEKLURY with chloroquine phosphate or hydroxychloroquine sulfate is not recommended based on data from cell culture experiments, demonstrating potential antagonism, which may lead to a decrease in the antiviral activity of VEKLURY.

Adverse reactions
• The most common adverse reaction (≥5% all grades) was nausea.
• The most common lab abnormalities (≥5% all grades) were increases in ALT and AST.

Dosage and administration
— Administration should take place under conditions where management of severe hypersensitivity reactions, such as anaphylaxis, is possible.

ECMO=extracorporeal membrane oxygenation.
In the ACTT-1 overall study population, patients experienced

5 DAYS SHORTER RECOVERY TIME WITH VEKLURY

Median 10 days with VEKLURY vs 15 days with placebo; recovery rate ratio: 1.29 (95% CI, 1.12 to 1.49), P<0.001.1,2

- Recovery was defined as patients who were no longer hospitalized or hospitalized but no longer required ongoing COVID-19 medical care

Significantly greater likelihood of improvement in clinical status, a key secondary endpoint

- Patients were 54% more likely to have improved clinical status on Day 15 vs placebo; odds ratio for improvement: 1.54 (95% CI, 1.25 to 1.91)

Helped reduce progression to more severe disease, an additional secondary endpoint

- 7% absolute reduction in incidence of new noninvasive ventilation or high-flow oxygen with VEKLURY (17%, n=307) vs placebo (24%, n=266) in patients who did not receive either at baseline (95% CI, -14 to -1)
- 10% absolute reduction in incidence of new mechanical ventilation or ECMO with VEKLURY (13%, n=402) vs placebo (23%, n=364) in patients who did not receive either at baseline (95% CI, -15 to -4)

Adverse reaction frequency was comparable between VEKLURY and placebo

- All adverse reactions (ARs), Grades ≥3: 41 (8%) with VEKLURY vs 46 (9%) with placebo; serious ARs: 2 (0.4%)† vs 3 (0.6%); ARs leading to treatment discontinuation: 11 (2%)‡ vs 15 (3%)

ACTT-1 was a randomized, double-blind, placebo-controlled, phase 3 clinical trial in hospitalized patients with confirmed SARS-CoV-2 infection and mild, moderate, or severe COVID-19. Patients received VEKLURY (n=541) or placebo (n=521) for up to 10 days. The primary endpoint was time to recovery within 29 days after randomization. Secondary endpoints included clinical status of patients on Day 15 as assessed on an 8-point ordinal scale and incidence of new high-flow oxygen requirement or new mechanical ventilation or ECMO.†

† Seizure (n=1), infusion-related reaction (n=1)
‡ Seizure (n=1), infusion-related reaction (n=1), transaminases increased (n=3), ALT increased and AST increased (n=1), GFR decreased (n=2), acute kidney injury (n=3).

IMPORTANT SAFETY INFORMATION (cont’d)

Dosage and administration (cont’d)

- Treatment duration:
  - For patients who are hospitalized, VEKLURY should be initiated as soon as possible after diagnosis of symptomatic COVID-19.
  - For patients who are hospitalized and do not require invasive mechanical ventilation and/or ECMO, the recommended treatment duration is 5 days. If a patient does not demonstrate clinical improvement, treatment may be extended up to 5 additional days, for a total treatment duration of up to 10 days.
  - For patients who are hospitalized and require invasive mechanical ventilation and/or ECMO, the recommended total treatment duration is 10 days.
  - For patients who are not hospitalized, diagnosed with mild-to-moderate COVID-19, and are at high risk for progression to severe COVID-19, including hospitalization or death, the recommended total treatment duration is 3 days. VEKLURY should be initiated as soon as possible after diagnosis of symptomatic COVID-19 and within 7 days of symptom onset for outpatient use.
  - Testing prior to and during treatment: Perform hepatic laboratory and prothrombin time testing prior to initiating VEKLURY and during use as clinically appropriate.
  - Renal impairment: No dosage adjustment of VEKLURY is recommended in patients with any degree of renal impairment, including patients on dialysis. VEKLURY may be administered without regard to the timing of dialysis.

Pregnancy and lactation

- Pregnancy: A pregnancy registry has been established for VEKLURY. Available clinical trial data for VEKLURY in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes following second- and third-trimester exposure. There are insufficient data to evaluate the risk of VEKLURY exposure during the first trimester. Maternal and fetal risks are associated with untreated COVID-19 in pregnancy.

- Lactation: VEKLURY can pass into breast milk. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for VEKLURY and any potential adverse effects on the breastfed child from VEKLURY or from an underlying maternal condition. Breastfeeding individuals with COVID-19 should follow practices according to clinical guidelines to avoid exposing the infant to COVID-19.

Please see Brief Summary of full Prescribing Information on the following page.


VEKLURY, the VEKLURY Logo, GILEAD, and the GILEAD Logo are trademarks of Gilead Sciences, Inc., or its related companies.

© 2023 Gilead Sciences, Inc. All rights reserved. US-VKYP-0455 08/23
Hypersensitivity, Including Infusion-related and Anaphylactic Reactions: VEKLURY® (remdesivir)

Drug Interactions [Also see Warnings and Precautions, Adverse Reactions, and Use in Specific Populations]

Testing Before Initiation and During Treatment: Perform eGFR, hepatic laboratory, and prothrombin time testing prior to initiating VEKLURY and during use as clinically appropriate.

Recommended Dosage in Adults and Pediatric Patients ≥28 Days Old and Weighing ≥3 kg:
- For adults and pediatric patients weighing ≥40 kg: 200 mg on Day 1, followed by once-daily maintenance doses of 100 mg from Day 2, administered orally via intravenous infusion.
- For pediatric patients ≥28 days old and weighing ≥3 kg: 5 mg/kg on Day 1, followed by once-daily maintenance doses of 2.5 mg/kg from Day 2, administered orally via intravenous infusion.

Treatment Duration:
- For patients who are hospitalized and require invasive mechanical ventilation and/or ECMO, the recommended total treatment duration is 10 days. VEKLURY should be initiated as soon as possible after diagnosis of symptomatic COVID-19.
- For patients who are hospitalized and do not require invasive mechanical ventilation and/or ECMO, the recommended treatment duration is 5 days. If a patient does not demonstrate clinical improvement, treatment may be extended up to 5 additional days, for a total treatment duration of up to 10 days.
- For patients who are not hospitalized, diagnosed with mild-to-moderate COVID-19, and at high risk for progression to severe COVID-19, including hospitalization or death, the recommended total treatment duration is 5 days. VEKLURY should be initiated as soon as possible after diagnosis of symptomatic COVID-19 and within 7 days of symptom onset.

Renal Impairment: No dosage adjustment of VEKLURY is recommended in patients with any degree of renal impairment, including patients on dialysis. VEKLURY may be administered without regard to the timing of dialysis.

Dose Preparation and Administration: [See full Prescribing Information for complete instructions on dose preparation, administration, and storage]
VEKLURY must be prepared and administered under supervision of a healthcare provider and must be administered via intravenous infusion only, over 30 to 120 minutes. Do not administer the prepared diluted solution concomitantly with any other medication.
- VEKLURY for injection (supplied as 100 mg lyophilized powder in vial) must be reconstituted with Sterile Water for Injection prior to dilution in a 100 mL or 250 mL 0.9% sodium chloride infusion bag.
- Care should be taken during admixture to prevent inadvertent microbial contamination; there is no preservative or bacteriostatic agent present in these products.

Doseage Preparation and Administration in Pediatric Patients ≥28 Days of Age and Weighing 3 kg to <40 kg: The only approved dosage form of VEKLURY for pediatric patients ≥28 days of age and weighing 3 kg to <40 kg is VEKLURY for injection (supplied as 100 mg lyophilized powder in vial). Carefully follow the product-specific preparation instructions.

CONTRAINDICATIONS: [Also see Warnings and Precautions]
VEKLURY is contraindicated in patients with a history of clinically significant hypersensitivity reactions to VEKLURY or any of its components.

WARNINGS AND PRECAUTIONS: [Also see Contraindications, Dosage and Administration, Adverse Reactions, and Drug Interactions]
Hypersensitivity, Including Infection-related and Anaphylactic Reactions: Hypersensitivity, including infusion-related and anaphylactic reactions, has been observed during and following administration of VEKLURY; most reactions occurred within 1 hour. Monitor patients during infusion and observe for at least 1 hour after infusion is complete for signs and symptoms of hypersensitivity as clinically appropriate. Symptoms may include hypotension, hypertension, tachycardia, bradycardia, hypotension, fever, dyspnea, wheezing, angioedema, rash, nausea, diaphoresis, and shivering. Slower infusion rates (maximum infusion time <120 minutes) can potentially prevent these signs and symptoms. If a severe infusion-related hypersensitivity reaction occurs, immediately discontinue VEKLURY and initiate appropriate treatment.

Increased Risk of Transaminase Elevations: Transaminase elevations have been observed in healthy volunteers and in patients with COVID-19 who received VEKLURY; the transaminase elevations were mild to moderate (Grades 1-2) in severity and resolved upon discontinuation. Because transaminase elevations have been reported as a clinical feature of COVID-19, and the incidence was similar in patients receiving placebo versus VEKLURY in clinical trials, discerning the contribution of VEKLURY to transaminase elevations in patients with COVID-19 can be challenging. Perform hepatic laboratory testing in all patients.
- Consider discontinuing VEKLURY if ALT levels increase to >5 x ULN.
- Discontinue VEKLURY if ALT elevation is accompanied by signs or symptoms of liver inflammation.

Risk of Reduced Antiviral Activity When Coadministered With Chloroquine or Hydroxychloroquine: Coadministration of VEKLURY with chloroquine phosphate or hydroxychloroquine sulfate is not recommended. Remdesivir and its metabolites are in vitro substrates and/or inhibitors of certain drug metabolizing enzymes and transporters. Based on a drug interaction study conducted with VEKLURY, no clinically significant drug interactions are expected with inducers of cytochrome P450 (CYP) 3A4 or inhibitors of Organic Anion Transporting Polypeptides (OATP) 1B1/1B3, and P-glycoprotein (P-gp).

In Specific Populations: [Also see Dosage and Administration and Warnings and Precautions]

Pregnancy Risk Summary: A pregnancy registry has been established for VEKLURY. Available clinical trial data for VEKLURY in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage, or other maternal or fetal outcomes following second- and third-trimester exposure. There are insufficient data to evaluate the risk of VEKLURY exposure during the first trimester.

Lactation Risk Summary: A published case report describes the presence of remdesivir and active metabolite GS-441524 in human milk. Available data (n=11) from pharmacovigilance reports do not indicate adverse effects on breastfed infants from exposure to remdesivir and its metabolite through breastmilk. There are no available data on the effects of remdesivir on milk production. In animal studies, remdesivir and metabolites have been detected in the nursing pups of mothers given remdesivir, likely due to the presence of remdesivir in milk. In developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for VEKLURY and any potential adverse effects on the breastfed child from VEKLURY or from the underlying maternal condition. Breastfeeding individuals with COVID-19 should follow practices according to clinical guidelines to avoid exposing the infant to COVID-19.

Pediatric Use The safety and effectiveness of VEKLURY for the treatment of COVID-19 have been established in pediatric patients ≥28 days old and weighing ≥3 kg. Use in this age group is supported by the following:
- Trials in adults
- An open-label trial (Study GS-US-540-5823) in 53 hospitalized pediatric subjects

Geriatric Use

OVERDOSAGE

There is no human experience of acute overdose with VEKLURY. Treatment of overdose with VEKLURY should consist of general supportive measures including monitoring of vital signs and observation of the clinical status of the patient. There is no specific antidote for overdose with VEKLURY.
By Teresa Caponiti

SHM’s 2023 State of Hospital Medicine Report includes new data on hospital medicine as it is now and how it’s evolved during the last three years. The 2023 SoHM Report also includes results from the inaugural Hospital Medicine Workforce Experience Survey, designed to provide insight into individual hospitalists’ experiences with workplace structures, including backup systems and patient census. Survey questions also included queries about participants’ levels of well-being, burnout, and engagement. Where possible, the 2023 SoHM Report provides an analysis of the intersection between these data points and workplace structures.

Unsurprisingly, hospital medicine faces challenges with burnout, which The Hospitalist has covered extensively. Despite this, most hospitalists reported feeling full of meaning and purpose and noted that they were able to use their skills to make a meaningful difference. The data are helping SHM and, we hope, group leaders across the field, think of ways to better support frontline hospitalists and the hospital medicine team. This new Workforce Experience Survey adds important complementary data to the traditional group-level responses.

Previous readers of the report may note that the 2023 SoHM Report has a smaller sample size than in recent years, with 373 groups participating. However, even with this smaller sample size, more hospitalists are represented in the data than ever before. SHM estimates the data comprised approximately 20% of the hospitalists practicing nationwide.

SHM hypothesizes that the smaller sample size is due to a variety of factors, including the consolidation of hospital medicine groups, as this trend has continued for several years. For the last several reports, the number of groups participating has trended downward, but the average number of physicians participating grew. The average number of hospitalists grew in every region, and most groups report that they will add full-time equivalents in the coming year. Furthermore, the sample size could be related to the timing of the survey, which even with this smaller sample size, more hospitalists are represented in the data than ever before. SHM estimates the data comprised approximately 20% of the hospitalists practicing nationwide.

“Use the SoHM Report for everything from looking at productivity, compensation, and scope of practice to operational structure for other practices. I love how it provides information on where we could be as a group or highlights areas to focus on as leaders.”

–Romil Chadha, MD, MPH, SFHM

Use the 2023 State of Hospital Medicine Report to help make informed decisions in the coming year as hospitalists and healthcare systems continue to navigate the future of the specialty. Order Today at hospitalmedicine.org/sohm
Bedside Rounding—Is it Right for You?

By Vanessa Caceres

Bedside rounding, a practice dating back more than a century is not uniformly implemented. Many physicians are unsure of its effectiveness in improving patient care and teaching learners, and it conflicts with many pandemic protocols.

Some hospitalists suggest selecting patients or scenarios for bedside rounding instead of meeting in a conference room or catching colleagues in the hallway. Others believe it should be used for all patients.

### The pros

Many clinicians see advantages to bedside rounding; for one, patients seem to like it.

“When done well, everyone benefits,” said Annie Massart, MD, assistant professor of medicine at Emory University in Atlanta. “The literature suggests that patients prefer it, which makes sense because it’s an important tool for centering our patients in their care.” Dr. Massart, who says she’s passionate about bedside rounds, describes the opportunity to foster shared decision-making as one major pro for bedside rounding.

In pediatrics, involving patients—or, more accurately their parents—in decision making is the norm, says Christopher Landrigan, MD, MPH, chief, division of general pediatrics at Boston Children’s Hospital in Boston and the William Berenberg Professor of Pediatrics at Harvard Medical School. This helps to keep them informed and involved with their child’s care. Still, Dr. Landrigan thinks bedside rounding can translate into adult medicine well and that the biggest barrier is the hospital culture.

Another advantage to bedside rounding is that it can help trainees grow as more experienced physicians can observe them and provide granular feedback. Dr. Massart said, ‘’Learners want to improve and are tired of being told to ‘read more’ at the end of each rotation. When I’ve spent each morning with them at the bedside, I’m able to observe their exam skills and give them nuanced feedback on how they connect with their patients.”

Specifically bedside rounds can help assess trainees on empathy, how they answer patient questions, how they relay a plan with minimal medical jargon, and how they navigate language and cultural barriers, says Ali Farkhondehpour, MD, FACP, FHM, associate clinical professor with the University of California San Diego, and a hospitalist in the division of hospital medicine at UC San Diego Medical Center.

Bedside rounding also can be just as, or more, efficient compared to other methods. A Journal of Hospital Medicine article found that when comparing bedside rounds to walking rounds, the time spent on them per patient tends to be similar. However, it may not feel that way, says John T. Ratelle, MD, associate professor of medicine and a hospitalist at the Mayo Clinic in Rochester, Minn. “There’s some upfront investment required. It’s a learned skill. It’s hard to go into a room and talk to a patient about their conditions with them as well as to attendings and professional staff,” he said. He describes bedside rounding as cognitively more demanding, which is likely what makes it feel longer.

“They may be in the minority, but bedside rounding is also what just seems to work best for some hospitalists. Dr. Ratelle worked previously with an intern who was trained early on in bedside rounding and actually preferred it to other methods.”

### The cons

Of course, if bedside rounds were perfect, everyone would use them. Yet they have some drawbacks.

As Dr. Ratelle mentions, the cognitive demands of bedside rounding compared with simply meeting with peers outside of the patient’s room could make the latter approach preferable. The current demands on medical professionals in hospitals combined with the idea of doing bedside rounds may sound overwhelming. “It’d be cognitively less demanding to meet in a conference room that’s a safe space,” he said. “I think that’s one reason why bedside rounding is withering.”

Another reason that bedside rounding may be used less frequently is that many hospitals are still in “COVID mode,” even if the threat of the virus is less foreboding than it once was. The routine of discussing care outside of the patient’s room continues at many medical centers, Dr. Farkhondehpour says. Some are pushing to return to pre-COVID bedside routines while others are sticking with the methods they have used over the past few years. “I think this has become an ‘old habits are hard to break’ scenario,” he said.

Bedside rounds may not be the right choice for every patient scenario, Dr. Farkhondehpour says. For instance, complex goals-of-care discussions are often lengthy, especially when hospice may be part of it. “The mornings are hard to initiate a meaningful goals-of-care discussion and then leave and come back to pick up where you left off from,” he said.

### Hybrid method

While some hospitalists may have a strong proclivity for bedside rounding or card flipping in internal medicine, Dr. Ratelle says the right answer may be somewhere in between, deciding which scenarios would benefit the most from bedside rounds.

First, you need to be with a patient who needs it and benefits from it, he says.

Next, you need a leader who feels comfortable at the bedside. “Often that’s the attending physician, but it doesn’t have to be,” Dr. Ratelle said. Leadership support from the hospital system is also crucial.

The third factor is having the time and space to do a bedside round. If the workload for a particular day seems manageable, that also sets the day up for bedside rounding. However, Dr. Landrigan points out, research finds the time it takes is about the same as conference-room rounds.

Dr. Farkhondehpour favors a hybrid model of bedside rounding for new patients admitted overnight or patients with new acute overnight events, a table round or card flip on patients who tend to be stable with less acute medical issues, and a walk-around on all others.

Dr. Landrigan prefers using bedside rounds for all patients, even if that creates a mental framework and additional education and coaching. “Because bedside rounds have been shown to broadly improve care, there is a risk that if you pick and choose whom you’re going to do them on, systemic bias might creep in. Better to do them for everyone, and do them well,” he said.

Vanessa Caceres is a medical writer in Bradenton, Fl.

### References


*In addition to the references, the following articles and website provide other background and perspectives related to bedside rounds.*

8 Tips for Better Bedside Rounding

There are a few guiding principles to keep in mind if you want to push for more bedside rounding at your medical center.

1. Get the right people on board. This includes hospital leadership as well as at least one influential hospitalist who will support and use bedside rounding. Dr. Landrigan says. If they are on board, others will follow.

2. Set expectations on the first day of training. Dr. Farkhondehpour advises explaining the benefits of bedside rounds to the team, including confirmation of patient history, teaching physical exam techniques, the assessment of communication skills, and the benefit of having these discussions with patients and the family to reduce returns to the bedside. For those new to bedside rounds, it can be helpful to start with some cases that are not medically complex, to set them up for success.

3. Prepare participants with some basic health-literacy concepts. With I-PASS, a methodology for patient-centered decision-making and patient handoff that has been developed and researched by Dr. Landrigan, one key component is training medical staff to use simpler health terms when possible. So, instead of saying, “The patient had a fever and high blood pressure,” you could say, “The patient has a fever and high blood pressure.” Getting out of “medical speak” will make the information you share easier for patients to follow during bedside rounds.

4. Consider which conversations are best for bedside rounds and which are better for afternoon discussions with patients. If you need a complex goals-of-care discussion or have to deliver bad news to a patient (like a cancer diagnosis), that may be better served during times other than morning bedside rounds, Dr. Farkhondeshpour says. An afternoon visit may be a less rushed time to discuss the next steps and the prognosis, he says.

5. Use the teach-back method with patients. After devising a treatment plan during a bedside round, Dr. Landrigan recommends saying to the patient or their parents or caregivers, “I know we’ve gone through a lot of information, but can you tell me what you understand the plan to be?” He says this helps confirm what they understood. “In medicine, we often just hope that they’ll grasp it, which isn’t often the case,” he said.

6. If you’re the physician training another physician, make it clear to patients who their doctor is. Dr. Massart likes to introduce herself as “the supervising physician, working with your doctor, Dr. Smith,” to highlight the physician learner as their doctor. “When the trainee presents at the bedside and I ask them about the plan for the day, patients get to see the intern or student owning their plan of care,” she said. This is in contrast with team rounds in the conference room, where patients inevitably see Dr. Massart as their doctor if she’s the one doing updates after rounds.

7. Involve technology when possible. “Whether it’s a computer on wheels or an iPad, having a computer on rounds is very helpful for reviewing data and real-time order entry,” Dr. Massart said. She mentions a study done that asked interns at Emory about facilitators and barriers for bedside rounds; it found that readily accessible workstations on wheels were part of the “secret sauce” to an optimal rounding experience.

If or when available, technology that patients can use—be it a tablet where they can easily see information such as the medications they are using, or a portal they can access—also could be part of the experience.

8. Be flexible. Every patient, learner, and situation is different. By staying flexible with trainees and patients, you can better meet their needs, Dr. Ratelle says. Thoughtful planning for when and how to use bedside rounds can help avoid situations like the one Dr. Massart had as a resident when an attending had the whole team do bedside rounds from 9 a.m. to 3 p.m. without a lunch break.

“Every time I attend SHM Converge, I walk away feeling engaged and excited. My brain is always full with content and my heart is full of connections and comradery.”

~ Avital Y. O’Glasser, MD, SFHM

Register now for SHM Converge 2024 to secure the best rate. Join us for an exceptional hospital medicine experience spanning three days of professional and social engagement. Extend your stay to four days by attending one of our three Advanced Learning Courses.

At the event, you will:

- Get insights into the latest hospital medicine trends
- Network with colleagues nationwide
- Hear from experts in our field
- Be inspired by innovative ideas
- Explore the beautiful surroundings of San Diego

Save more by booking early. Receive exclusive discounted rates from our hotel partners and get the lowest possible conference rate with the early-bird savings.

Early-Bird Registration

shmconverge.org

~ Avital Y. O’Glasser, MD, SFHM
Most working hospitalists will see cancer patients regularly on their hospital rounds since it’s the main underlying condition for many hospital admissions—whether for the disease itself, side effects from cancer treatments, or possibly coincidental medical issues. But a smaller number of hospitalists are focusing their practices on oncology patients, working with oncologists who—like many outpatient-based physicians before them throughout the history of hospital medicine—have found it ever harder to make in-person visits to their patients in the hospital.

At Memorial Sloan Kettering Cancer Center (MSKCC) in New York, which has one of the first and largest oncology hospitalist groups with nearly 60 members, the hospitalists assume responsibility for managing the care of patients admitted to the cancer center, consulting when needed by phone or email with the patients’ oncologists.

“We were founded 15 years ago when I was hired as Memorial’s first hospitalist,” said Barbara Egan, MD, FACP, SFHM, chief of the hospital medicine service at MSKCC. “I think it started as something of an experiment by the chief of gastroenterology oncology at the time, Dr. David Kelsen, who had an insight that what was bringing cancer patients into the hospital was mostly internal medicine problems like symptom management, infections, and late- or end-stage disease management.” These did not require the expertise of a medical oncologist, she explained.

“He convinced me to hire me, and so I fell into the role. I was intrigued by the opportunity to start something new and to see where it could go. The experiment went swimmingly.”

Hospitalists’ added value

Oncology hospitalists typically are internal medicine physicians who care for acutely ill, hospitalized cancer patients, working closely with their outpatient oncologists. At MSKCC, the hospitalists’ added value to the health system is to free up the oncologists so they can spend more time in the system’s varied outpatient clinic settings, bringing more patients into the system, as well as on clinical trials and advancing oncology science.

In other settings, the oncology hospitalist (or onco-hospitalist) may co-manage cancer patients with their oncologist, whether in a cancer hospital, a cancer unit of a general hospital, or scattered around the hospital. There are also board-certified oncologists who perform the hospitalist’s inpatient role for defined periods of time, based on oncology settings within a hospital.

Little research has been published on outcomes for onco-hospitalists. One recent study from the Yale Cancer Center and Smilow Cancer Hospital in New Haven, Conn., published in May in the Journal of Hospital Medicine, found that oncology hospitalists decreased lengths of hospital stay, increased inpatient capacity, and reduced reported job stress among oncologists—while maintaining high-quality inpatient care.

“We’re not unique for cancer centers, and we weren’t trailblazers,” said Jens Morris, MD, the study’s lead author and director of the hospitalist service at Smilow. “Most major cancer centers now have onco-hospitalists. Here at Yale, the oncologists were expected to be responsible for caring for their hospitalized patients. But among the oncologists themselves, there was a growing sense that maybe inpatient care was out of their wheelhouse. That is, with this complex, high-acuity inpatient medical management would be better served by having a hospitalist take the lead.”

Geographically, Yale oncologists are spread across most of Connecticut, often too far to come to the hospital in person. The patients have medical-care needs all day long, and that wasn’t something their oncologists could provide. Plus they have so many other demands on their time, said Dr. Morris, who has been a hospitalist since 2002.

“We established this program so we can reassure the patient that their oncologist is in the loop, making management decisions with us,” said her hospitalist colleague, Erin Gombos, MD.

“When the patient is in the hospital, we reach out to the oncologist to give them the back story,” Communication is frequent, typically by email. “Realistically, the management is mostly up to us, and then when the patient is ready for discharge, we get back to them with a full report,” Dr. Gombos said.

Earning the oncologists’ trust

“We gained traction and our program took off when we earned the medical oncologists’ trust by demonstrating to them that we did our job well,” Dr. Egan said. “For them to be able to allow us to join the team at MSKCC, even for the short period of time the patient is in the hospital, and take over the day-to-day care of the patient, they have to be able to trust us.”

The learning curve for this job is long and steep, and turnover by the hospitalists would have been a program killer. “It’s too much of an investment to get people up to speed in this subspecialty area and then have them leave.” That has meant recruiting and retaining strong clinicians who can learn, on the job, a working knowledge of oncologic conditions and treatments, she said.

But it is particularly challenging since new onco-hospitalists at MSKCC are asked to spend their first few years as nocturnists, only working night shifts. “Because the nature of hospital medicine at MSKCC is so sub-specialized to begin with, someone coming straight out of residency is better served to be a nocturnist. They run the entire hospital overnight, from seven to seven, admitting all the overnight patients, getting oriented to the full breadth of what we do. Eventually, they’ll focus on one or a few oncology groups,” Dr. Egan said.

“For us, another key was finding people who were drawn to the palliative-medicine piece, which is a huge part of what we do. Within our group, we do ongoing seminars on palliative care, improving our communication skills and symptom management.”

A significant percentage of cancer patients who get admitted to MSKCC are probably in the last six to eight months of their lives, even the ones who appear to be doing well,” she said. A hospital admission often means something has gone wrong, and it can become almost a turning point in their cancer journey. “They’re in the hospital because the current line of chemotherapy isn’t working, or they have symptom problems related to the progression of their cancer.

It’s an opportunity to take a step back and take stock: Are we on the right path? Is it time to change direction?”

Other oncology hospitalists agree that palliative care is a large part of what they do, even with recent dramatic advances in cancer therapy leading to new cures. However, the hospitalist doesn’t point patients down an end-of-life pathway without first consulting with their oncologists, many of whom have become increasingly skilled at transitioning their patients to hospice or end-of-life approaches when these become appropriate.

Day-to-day management

Darren Boyd, MD (°DrDarren-Boyd), hospitalist and medical director of the oncology hospitalist service at Northwestern Memorial Hospital in Chicago, says Northwestern’s cancer patients occupy about 100 beds spread across three floors of the 900-bed hospital. “Cancer patients come from our hospital’s ER, from our outpatient clinics, and as transfers from smaller satellite hospitals. At the moment we have a mix of models, including a resident-staffed acute leukemia inpatient service, a nurse-practitioner-staffed stem cell transplant service, a physician-assist ant-staffed malignant hematology service, and the solid organ tumor service, which is managed by the hospitalist.”

From Northwestern’s hospitalist service, which includes about 100 hospitalists, three attendings are assigned to the oncology unit on any given day, he said. Each attending manages 12 patients, and they work one week on and one week off. “Just like general hospitalists, we’re responsible for the day-to-day management of patients, but in this case, all have a known diagnosis of cancer. We perform the same tasks as any hospitalist: seeing patients, interacting with consultants, ordering tests,” Dr. Boyd said. “Where I’d say we differ is in the closer, more frequent communication with the patient’s oncologist throughout the stay.”

Dr. Boyd remembers his oncology rotation when he was a medical resident as a busy one, caring for very sick acute leukemia patients whose conditions changed hour by hour. After residency, he remembers saying he’d give it a try to take

Onco-Hospitalists Bring Value to Patient Care

Their role as hospital representatives of the oncology care team
SHM Oncology Hospitals SIG

SHM’s Oncology Hospitals Special Interest Group (SIG) debuted earlier this year. This SIG is for SHM members interested in pursuing oncology hospital medicine full-time, or just learning more about the field for importing into their general practices. Drs. Barbara Egan and Jensa Morris are the co-facilitators of the SIG. “I’d hope we can be a big tent for hospitalists and a source of information, support, and resources for each other as we grow this field,” Dr. Egan said.

Team-based approach

At MD Anderson Cancer Center in Houston, hospital medicine is the largest inpatient service. The department includes physicians, advanced practice practitioners, pharmacists, and internal medicine residents—two onc-hospitalist fellowships offering one or two years of advanced clinical and research training for internal medicine graduates who likely will go on to become academic onc-hospitalists. This is one of the country’s more mature oncology hospitalist programs, with a focus on patient care, quality improvement, education, and research. During the COVID-19 pandemic, the onco-hospitalists also assumed COVID-19 care responsibility for all hospitalized cancer patients, coordinating care with multiple disciplines across the institution.

Josiah Halm, MD, has been an onco-hospitalist at MD Anderson for the past 15 years and currently is its interim chair of hospital medicine. “We take care of solid tumors but not leukemia, lymphoma, or other liquid tumors. Most of our patients have established relationships with oncologists, but some patients show up at our emergency room without one. Others may have been directed by their doctor to seek a second opinion or go to hospice or were given a suspicion of cancer. Our job is to expedite the workup of admitted patients, establish the diagnosis, and coordinate appropriate disposition with our oncology or palliative care colleagues,” he said.

“We cherish the team-based approach practiced at MD Anderson. There can be a whole group of specialists sitting in one room, talking about one patient, and this approach has translated to us. We also get involved in research, not necessarily clinical trials but health services research and quality improvement.” Quality projects have addressed venous thromboembolisms, glycemic control, readmissions, discharge times, and patient experience.

The field of oncologic treatment is rapidly changing. Dr. Halm said, “Immunotherapy, targeted therapy, and T-cell therapy are now becoming the cornerstones of some cancer treatment. They often come with significant side effects and comorbidities, which has spawned a whole new area of learning in onco-medicine and hospitalist co-management.”

Deeper relationships

Onco-hospitalists meet patients in a time of crisis, Dr. Egan said. “We quickly form deep and meaningful relationships because it is a crisis point and we are being asked to shepherd them through that. We also free up the oncologists to do what’s most satisfying for them and most strategic for the institution. It allows us to make a place for ourselves, where we’re valued for what we can do,” she said.

Patients expect us to be up to date on the most recent developments in cancer therapies. Our professional development emphasizes keeping up to date, and we also lean on our medical oncologist colleagues. We see patients in first-in-human studies, where they come in with medical problems that haven’t even been reported yet.”

In her role at MKSCC, Dr. Egan has also gotten involved with the work of improving end-of-life care for the entire institution. “We’ve partnered with our Patient and Family Advisory Council for Quality, which represents the patient and family’s voice for a lot of initiatives here. They have recently stepped up to the plate in improving end-of-life care—as the number-one item on their agenda for the next two years,” she said.

“What we’ve been learning from patients and families is that, yes, many do want to be part of cutting-edge, experimental therapies. But when that is no longer possible, they want the opportunity to have their voice heard and a say in what end-of-life care looks like for them. Those are not mutually exclusive goals.”

Larry Beresford is an Oakland, Calif.-based freelance medical journalist, specialist in hospice and palliative care and long-time contributor to The Hospitalist.

Reference

Infectious causes

The organisms known to cause cavitary lung lesions are many and include bacteria, fungi, parasites, and viruses (Table 1). Principal among them for consideration, particularly from an infection-control standpoint, is *Mycobacterium tuberculosis* (TB) and *Staphylococcus aureus*. Lung abscesses and necrotizing pneumonias, subsets of cavitary lung lesions, carry another unique spectrum of causative organisms. Anaerobic and microaerophilic streptococci (e.g., *Streptococcus milleri*) make up the majority of identified organisms, and polymicrobial infection is commonly encountered.10 Other non-tuberculous mycobacteria such as *M. abscessus* and *M. avium* also cause cavitary lung lesions. Notable aerobic organisms occasionally encountered include *Staphylococcus aureus* and *Klebsiella pneumoniae*.9 Fungi and parasites, while rarer than bacterial causes, require significantly different treatment regimens. *Aspergillus fumigatus* in its invasive form is known to occupy preexisting lung cavities and is identifiable by the presence of a fungal ball (aspergilloma) within the lung cavity.7 Other endemic fungi (e.g., *Histoplasmosis capsulatum*) have been linked to cavitary lung lesion development.6

Lung cavitation in the setting of COVID-19 infection

Since the COVID-19 pandemic began, several cases of lung cavitations in the setting of COVID-19 infection have been reported. In a single-center study reporting on the radiographic appearance and clinical outcomes of 689 hospitalized patients with COVID-19 pneumonia, 3.3% of patients developed lung cavitation. Cavity sizes ranged from 30 to 100 mm in diameter and were solitary or multiple. Bacterial and fungal coinfections were noted in some but not all patients. Notably, cavitations appeared on subsequent or not initial chest imaging in all patients, suggesting lesions represented a delayed complication of COVID-19 infection.6 Microbiologicals of cavitation are not fully known but autopsy data have suggested a mixture of thrombotic vascular occlusion accompanied by liquefying necrosis contributing to cavity development. Lung cavitation in the setting of COVID-19 pneumonia appears to be a poor prognostic indicator, with death occurring in 50% of patients in the aforementioned case series.9

Non-infectious causes

Several non-infectious causes of lung cavitations exist and should be considered in the differential. These include malignant, rheumatologic, vascular, and infiltrative conditions. A principal consideration of a lung cavity is malignancy. Both primary lung cancers and metastatic cancers are known to cause cavitations, with cancers of squamous cell origin being the cell type most known to cavitate.11 Several rheumatologic conditions have also been linked to lung cavitation. Granulomatosis with polyangiitis, rheumatoid arthritis, and sarcoidosis are all known to cause cavitation. Other less common causes of lung cavitation include pulmonary embolism (usually resulting from pulmonary infarction), Langerhans cell histiocytosis, and amyloidosis.7

Patient characteristics

A focused pulmonary history is essential in guiding the workup. Conditions such as substance use disorders, seizures, or swallowing deficits put patients at risk for aspiration, which is the most common cause of pulmonary abscesses. Immunosuppression, particularly neutropenia or hematologic malignancies, greatly raise the likelihood of infections from fungi and atypical bacteria. Carcinogens such as tobacco smoke or occupational exposure increase the primary lung cancer risk. Finally, circumstances such as travel to endemic regions, homelessness, incarceration, or sick contacts increase the risk of atypical infections such as *Mycobacteria* or coccidioidomycosis.

Imaging characteristics

While establishing a diagnosis from radiographic findings alone is unlikely, certain imaging cues can narrow the differential. Apical lung lesions are more commonly seen with tuberculosis and primary lung cancer, while the lower lobes are more often involved in necrotic pneumonias, septic emboli, or metastatic disease. Multiple cavitary lesions are more common in autoimmune disease, atypical infections, or metastatic cancer, whereas solitary lesions are more common with primary lung cancer or lung abscesses. Cavity-wall thickness has also been proposed as an effective tool, with thicknesses greater than 2 cm highly associated with malignancy and benign lesions frequently having thin walls of less than 7 mm. Lastly, findings such as associated consolidation or tree-in-bud nodules are more likely to be infectious, while a visible mass within a cavity is almost pathognomonic for an aspergilloma.

Initial diagnostics

Prior to infectious disease or pulmonary consultation, the hospitalist should consider obtaining a sputum smear for acid-fast bacilli. If a patient is asymptomatic but at risk for aspiration, a transtracheal aspirate may be ordered depending on the likelihood of certain diagnoses on the differential (see Table 2 for suggested pre-consultation evaluation). Additional, more advanced testing may be ordered depending on the likelihood of certain diagnoses on the differential. Bronchoscopy or biopsy? While often the etiology of a cavitary lesion can be determined through a focused history and non-invasive workup, certain conditions, particularly from an infection-control standpoint, are known to cause cavitations, with cancers of squamous cell origin being the cell type most known to cavitate. Other non-tuberculous mycobacteria such as *M. abscessus* and *M. avium* also cause cavitary lesions. Notable aerobic organisms occasionally encountered include *Staphylococcus aureus* and *Klebsiella pneumoniae*. Fungi and parasites, while rarer than bacterial causes, require significantly different treatment regimens. *Aspergillus fumigatus* in its invasive form is known to occupy preexisting lung cavities and is identifiable by the presence of a fungal ball (aspergilloma) within the lung cavity. Other endemic fungi (e.g., *Histoplasmosis capsulatum*) have been linked to cavitary lung lesion development.

Lung cavitation in the setting of COVID-19 infection

Since the COVID-19 pandemic began, several cases of lung cavitations in the setting of COVID-19 infection have been reported. In a single-center study reporting on the radiographic appearance and clinical outcomes of 689 hospitalized patients with COVID-19 pneumonia, 3.3% of patients developed lung cavitation. Cavity sizes ranged from 30 to 100 mm in diameter and were solitary or multiple. Bacterial and fungal coinfections were noted in some but not all patients. Notably, cavitations appeared on subsequent or not initial chest imaging in all patients, suggesting lesions represented a delayed complication of COVID-19 infection. Microbiologicals of cavitation are not fully known but autopsy data have suggested a mixture of thrombotic vascular occlusion accompanied by liquefying necrosis contributing to cavity development. Lung cavitation in the setting of COVID-19 pneumonia appears to be a poor prognostic indicator, with death occurring in 50% of patients in the aforementioned case series.

Non-infectious causes

Several non-infectious causes of lung cavitations exist and should be considered in the differential. These include malignant, rheumatologic, vascular, and infiltrative conditions. A principal consideration of a lung cavity is malignancy. Both primary lung cancers and metastatic cancers are known to cause cavitations, with cancers of squamous cell origin being the cell type most known to cavitate. Several rheumatologic conditions have also been linked to lung cavitation. Granulomatosis with polyangiitis, rheumatoid arthritis, and sarcoidosis are all known to cause cavitation. Other less common causes of lung cavitation include pulmonary embolism (usually resulting from pulmonary infarction), Langerhans cell histiocytosis, and amyloidosis.

Patient characteristics

A focused pulmonary history is essential in guiding the workup. Conditions such as substance use disorders, seizures, or swallowing deficits put patients at risk for aspiration, which is the most common cause of pulmonary abscesses. Immunosuppression, particularly neutropenia or hematologic malignancies, greatly raise the likelihood of infections from fungi and atypical bacteria. Carcinogens such as tobacco smoke or occupational exposure increase the primary lung cancer risk. Finally, circumstances such as travel to endemic regions, homelessness, incarceration, or sick contacts increase the risk of atypical infections such as *Mycobacteria* or coccidioidomycosis.

Imaging characteristics

While establishing a diagnosis from radiographic findings alone is unlikely, certain imaging cues can narrow the differential. Apical lung lesions are more commonly seen with tuberculosis and primary lung cancer, while the lower lobes are more often involved in necrotic pneumonias, septic emboli, or metastatic disease. Multiple cavitary lesions are more common in autoimmune disease, atypical infections, or metastatic cancer, whereas solitary lesions are more common with primary lung cancer or lung abscesses. Cavity-wall thickness has also been proposed as an effective tool, with thicknesses greater than 2 cm highly associated with malignancy and benign lesions frequently having thin walls of less than 7 mm. Lastly, findings such as associated consolidation or tree-in-bud nodules are more likely to be infectious, while a visible mass within a cavity is almost pathognomonic for an aspergilloma.

Initial diagnostics

Prior to infectious disease or pulmonary consultation, the hospitalist should consider obtaining a sputum smear for acid-fast bacilli. If a patient is asymptomatic but at risk for aspiration, a transtracheal aspirate may be ordered depending on the likelihood of certain diagnoses on the differential (see Table 2 for suggested pre-consultation evaluation). Additional, more advanced testing may be ordered depending on the likelihood of certain diagnoses on the differential. Bronchoscopy or biopsy? While often the etiology of a cavitary lesion can be determined through a focused history and non-invasive workup, certain conditions, particularly from an infection-control standpoint, are known to cause cavitations, with cancers of squamous cell origin being the cell type most known to cavitate. Other non-tuberculous mycobacteria such as *M. abscessus* and *M. avium* also cause cavitary lesions. Notable aerobic organisms occasionally encountered include *Staphylococcus aureus* and *Klebsiella pneumoniae*. Fungi and parasites, while rarer than bacterial causes, require significantly different treatment regimens. *Aspergillus fumigatus* in its invasive form is known to occupy preexisting lung cavities and is identifiable by the presence of a fungal ball (aspergilloma) within the lung cavity. Other endemic fungi (e.g., *Histoplasmosis capsulatum*) have been linked to cavitary lung lesion development.
entities require a more invasive workup with bronchoscopy or percutaneous biopsy. If malignancy is of primary concern, consultation with a pulmonologist should occur to help determine the feasibility of a bronchoscopic biopsy or if interventional radiology is required. Certain patients such as those with hematologic malignancies or immunosuppression are at higher risk for atypical infections and may benefit from earlier bronchoscopy to guide antimicrobial therapy.

### What to do at hospital discharge
The frequency of surveillance imaging for cavitary lung lesions will vary based on the etiology. In the case of malignancy, it is determined by cell type, initial staging, and treatment plan. A common question for hospitalists, however, is what the appropriate follow-up and monitoring should be, specifically for lung abscesses. Patients should typically receive an empiric trial of antibiotics before more invasive measures are attempted, as approximately 90% will improve with antibiotic therapy alone.\(^{10,12}\) Resolution on imaging may take several weeks or months and serial chest imaging should be obtained to monitor progress through the course of treatment.\(^{12}\) A strategy for imaging can include a repeat CT four to six weeks into treatment with subsequent imaging depending on clinical and radiographic status.

Should a lung abscess fail to improve with conservative therapy in the expected timeframe (or if the patient demonstrates clinical deterioration), pulmonology consultation is warranted for further diagnostic workup, typically with bronchoscopy to obtain further culture data and look for obstruction.\(^{10}\) Failure to improve despite an adequate trial with appropriate antibiotics may necessitate percutaneous drainage, endobronchial drainage, or, rarely, surgical resection. Depending on abscess location and local expertise, pulmonology, interventional radiology, and/or thoracic surgery consultations may be necessary to guide the next steps in management.\(^{11}\)

### Back to the case
After initial diagnostics, the patient was started on empiric antibiotics and discharged home with outpatient imaging follow-up. Subsequent chest imaging demonstrated resolution of cavitation and the cause was attributed to aspiration.

### Bottom line
Hospitalists are central to driving the care for hospitalized patients with cavitary lung lesions found on imaging.

### References
In 2019, I accepted a position at the University of Rochester’s Strong Memorial Hospital in Rochester, N.Y. I knew this wouldn’t be bread-and-butter hospital medicine, but rather a unique hospitalist role in inpatient medicine in psychiatry; a medical-psychiatric unit where the majority of patients carry diagnoses of serious and persistent mental illness (SPMI). It’s a road less traveled, owing largely to the paucity of such units in U.S. hospitals.

The experience has been one of personal and professional growth. Like many internists, my primary exposure to patients with SPMI (major depression, bipolar disorders, schizophrenia, and borderline personality disorder) had occurred during the psychiatry clerkship in medical school, followed by sporadic encounters in residency, during which the mental-health diagnosis most often took a backseat to the acute medical problem.

Now, I spend my days surrounded by catatonia and clozapine; haloperidol and hallucinations; benzotropine and benzodiazepines. The practice of providing medical care for people with psychiatric conditions simply wasn’t part of my prior medical training, and thus I learned it on the job. Having now developed a level of comfort, and a better understanding of the patients and the practice, I seek to share some of the pearls I’ve gathered along the way.

One fact I didn’t appreciate early in my training, but that has become much clearer as I’ve spent more time with psychiatrists, is the reality that people with psychotic disorders, even on optimal therapy and without positive symptoms of schizophrenia, are likely still to possess negative symptoms, often including a degree of paranoia and mistrust that makes providing medical care more challenging, even if they may not need acute psychiatric care. It’s worth noting this mistrust may arise as much from historically unfavorable interactions with the health care system as from psychopathology. This means building trust and forging a therapeutic partnership tends to require more time and effort than in the general population. Therefore, I’ve found the benefits of operating a medical-psychiatric unit that endeavors to care for SPMI inpatients whenever possible is a level of continuity that for some patients and clinicians approaches what’s found in primary care.

The approaches I’ve found most fruitful working with patients with psychotic disorders are those that I already strive for with other patients, but benefit from greater emphasis—listening, meeting someone ‘where they are,’ respecting autonomy, and reducing unnecessary interventions. Understanding how, for instance, a schizophrenic patient sees and interacts with the world is very important if you are to reach them therapeutically. This requires patience and may not be accomplished in a single visit. Obtaining collateral information from family and other contacts is highly recommended.

Defty setting the stage for interaction with the patient is beneficial; presenting as polite, respectful, and unhurried can put patients at ease. I usually knock or otherwise announce myself before entering the room (the response to this will often be your first clue as to how receptive a patient is likely to be), provide at least a warning if a light is to be switched on, and sit down if a chair is available. The building of trust starts early in the interaction; it’s best to start open-ended and patient-centered (e.g., “How can I help you today?”) without a hint of agenda. While many patients have priorities that differ from those of their physician, you may find that phenomena to be particularly pronounced in this population. Addressing their chief concern will increase the likelihood that you’ll be listened to later. You are likely to find that even if you’re patient-centered as possible, your patient may still decline medications and other interventions. In these cases, it is first crucial to understand why as explanation and clarification may be effective. If you find an interaction isn’t productive, sometimes returning at another time is useful. Often, declining care can be a patient’s means of communicating they’re feeling overwhelmed and need more time to process. If so, being flexible and offering medications and interventions multiple times throughout the day can prove successful. Of course, this requires buy-in from nursing and other members of the team. I’ve found that flexibility and teamwork are assets. Can the timing of medication administration be relaxed? Is it feasible to reduce the pharmaceutical burden to continue that which is relatively less important? What is your Plan B? A secondary plan that can be adhered to is universally preferable to a primary plan that empirically cannot. Formulating this secondary plan, of course, may necessitate participation by consulting services and may benefit from direct physician-to-physician communication in higher-complexity cases.

While psychotic disorders often respond readily to medication, not all psychiatric disorders do the same; certainly, few diagnoses color our preconceptions quite as vividly as borderline personality disorder. Marked by emotional volatility and instability of relationships, such patients may have a history of difficult interactions with health care professionals. It’s important to exercise insight into your own biases and emotional responses before you even set foot in the room; countertransference (transferring your emotions to the patient) will be the physician’s undoing. Clarity and consistency of communication and expectations are essential. This applies to patient interactions as well as to handoffs to other team members. Further, to mitigate the possibility of splitting (viewing individuals exclusively positively or negatively), rounding as a team is advisable (e.g., attending physician, advanced practice practitioner or resident, and bedside nurse) whenever practical.

The clinician needs to understand that while the behavior of a patient with borderline personality disorder may feel manipulative or vindictive, its motivation doesn’t generally rise to conscious awareness. Being aware that an observer’s perception of the patient’s actions is often not congruent with the patient’s intention can be a powerful tool in managing your emotional response to the interaction, and, indeed, a dispassionate approach will prove most efficacious and therapeutic for all parties.

All that being said, there will be times when a patient’s behavioral dysregulation will render an encounter unproductive or even counterproductive. In these instances, it’s necessary to set boundaries and terminate the encounter. The clinician can then return later when the patient is calm and amenable to continue the conversation.

In caring for patients with SPMI, it’s natural for the clinician to experience discomfort or disorientation. You may be tempted to attribute these sensations primarily to the patient. On the contrary, I’ve found these interactions have been ruthlessly revealing of growth opportunities in my own practice style; much of the discomfort is internally attributable. Bedside manner, patient-centeredness, and clear and consistent communication with patients, family, and other health care team members are less desirable than they are absolutely essential in this setting. I owe my patients a debt of gratitude for having shaped me into a better physician. I am privileged to have gained as much as I have given. ■

Dr. Bobeda

Dr. Bobeda is an assistant professor of psychiatry and medicine at the University of Rochester in Rochester, N.Y., and practices hospital medicine within the department of psychiatry, division of medicine in psychiatry services at Strong Memorial Hospital in Rochester, N.Y.

By Erik M. Bobeda, MD

October 2023

Lessons from a Med-Psych Unit
Immigrant Hospitalists Share Struggles and Discuss Paths to Progress

By Thomas R. Collins

Harsh Arora, MD, a hospitalist at Lovelace Medical Group in Albuquerque, N.M., said she has grown sad and frustrated by her long—and, so far, futile—effort to obtain an EB-1A, an employment-based visa for those demonstrating extraordinary ability in their field.

Out of the 140,000 employment-based visa petitions allotted each year, 7% is the maximum any country can get. Because of that, applicants from India must wait even longer due to the staggering number of applications received each year by U.S. Citizenship and Immigration Services.

Dr. Arora has worked in the U.S. on a work visa for his family with each breath. I’m just coming to the end of my rope,” she said. After remarks and the session ended, attendees approached her to offer support.

Many immigrant physicians currently live and work in the U.S. on temporary visas (J-1, H-1B) while waiting for a permanent visa to become available. Some remain in temporary status for many years, if not decades, because of the caps applied to their country of nationality.

Session presenters shared some statistics. A 2020 report by the Association of American Medical Colleges, shows the U.S. will likely see a shortage of between 37,800 and 124,000 physicians by 2034, including shortages in both primary and specialty care.1 In 2021, approximately one in five active U.S. physicians were born and attended medical school outside the U.S. or Canada, totaling more than 203,500 physicians.2

During the COVID-19 pandemic, 16.6% of health care workers were immigrants.3

“They served a lot, but immigrant hospitalists—many of them had ineligibility for Medicaid or social security benefits,” said Benji Mathews, MD, MBA, SFHM, department chair of hospital medicine at Regions Hospital, HealthPartners Institute, Minneapolis. Needing to work to remain in the U.S., there was a risk of deportation if an immigrant physician fell ill, he said. “That was a fear that many of our immigrant hospitalists lived through.”

Dr. Mathews recalled his move from the Middle East to Minnesota around his teenage years, and the challenges he experienced because English wasn’t his first language. He remembers constantly feeling like “the other” and has regularly experienced the common phenomenon of “perpetual foreigner syndrome.”

Patients, he said, often ask, “Where are you from?” which is often a harmless question, but one that is deeply personal and intimate. Some patients, he said, enjoy sharing about their sense of belonging, while others often quietly question it.

Dr. Mathews said he hopes to continue to serve and lead with SHM to provide spaces for immigrant hospitalists to share their stories and engage in advocacy.

Manpreet Malik, MD, SFHM, associate professor at Emory University School of Medicine in Atlanta, and a native of northern India said that in 2013 when he acquired an employment-based visa and applied for a green card, the U.S. was processing green card applications it had received in 2008. By 2019, when he switched jobs and went to Emory, it was processing applications received in 2005—so, over the course of six years, one year of progress had been made.

In 2022, he received his Employment Authorization Document, which allows him to work legally, and travel freely but still offers fewer privileges than a green card.

When he recently landed back in the U.S. from a global health trip, he remembers thinking, “I’m home.” And then the first line he needed to get into as he passed through immigration at the airport was the “foreign visitor line.”

“That was a big reality check,” Dr. Malik said.

For those on visas, life is full of headaches and work in the U.S. on temporary visas (J-1, H-1B) while waiting for a permanent visa to become available. Some remain in temporary status for many years, if not decades, because of the caps applied to their country of nationality.

Session presenters shared some statistics. A 2020 report by the Association of American Medical Colleges, shows the U.S. will likely see a shortage of between 37,800 and 124,000 physicians by 2034, including shortages in both primary and specialty care.1 In 2021, approximately one in five active U.S. physicians were born and attended medical school outside the U.S. or Canada, totaling more than 203,500 physicians.2

During the COVID-19 pandemic, 16.6% of health care workers were immigrants.3

“They served a lot, but immigrant hospitalists—many of them had ineligibility for Medicaid or social security benefits,” said Benji Mathews, MD, MBA, SFHM, department chair of hospital medicine at Regions Hospital, HealthPartners Institute, Minneapolis. Needing to work to remain in the U.S., there was a risk of deportation if an immigrant physician fell ill, he said. “That was a fear that many of our immigrant hospitalists lived through.”

Dr. Mathews recalled his move from the Middle East to Minnesota around his teenage years, and the challenges he experienced because English wasn’t his first language. He remembers constantly feeling like “the other” and has regularly experienced the common phenomenon of “perpetual foreigner syndrome.”

Patients, he said, often ask, “Where are you from?” which is often a harmless question, but one that is deeply personal and intimate. Some patients, he said, enjoy sharing about their sense of belonging, while others often quietly question it.

Dr. Mathews said he hopes to continue to serve and lead with SHM to provide spaces for immigrant hospitalists to share their stories and engage in advocacy.

Manpreet Malik, MD, SFHM, associate professor at Emory University School of Medicine in Atlanta, and a native of northern India said that in 2013 when he acquired an employment-based visa and applied for a green card, the U.S. was processing green card applications it had received in 2008. By 2019, when he switched jobs and went to Emory, it was processing applications received in 2005—so, over the course of six years, one year of progress had been made.

In 2022, he received his Employment Authorization Document, which allows him to work legally, and travel freely but still offers fewer privileges than a green card.

When he recently landed back in the U.S. from a global health trip, he remembers thinking, “I’m home.” And then the first line he needed to get into as he passed through immigration at the airport was the “foreign visitor line.”

“That was a big reality check,” Dr. Malik said.

For those on visas, life is full of headaches and limitations that others don’t have to live with, he said. Having to renew driver’s licenses whenever a visa needs to be renewed, difficulties obtaining loans; buying homes; and complexities with working independently.

The situation seems fundamentally unjust, he suggested.

“We have colleagues around the country who came in on visas, legally, and have been contributing to our community for a very, very long time,” he said. “We have to fix this!”

Rachel Thompson, MD, MPH, SFHM, immediate past president of SHM and chief medical officer at Snoqualmie Valley Valley Hospital in Snoqualmie, Wash., said that she used to have an ‘everything will work out’ mindset regarding immigration issues. A kind of wake-up call came when she tried to recruit physicians to the hospital medicine department for a former employer and was told, “We don’t do visas,” so she had to reject someone with a stellar resume. That physician went on to be a great addition to another university that did welcome physicians on visas.

Since then, she said she has been proud to be a part of SHM as the organization has promoted a diverse workforce that attempts to ease the hurdles faced by immigrant medical graduates. She pointed to SHM’s diversity and inclusion statement that says, “Diversity is a strength.”

“This is our workforce,” she said. “They’re here serving our communities, our people, and we shouldn’t be thinking about who is from where.”

Josh Boswell, JD, chief legal officer for SHM, said the focus of the U.S. health care system and the U.S. government should be on qualifications.

“Why? Because we need them here,” SHM is working for legislation that would remove the per-country cap and make other changes to ease the application process and protect children from aging out of dependent status at age 21. Dr. Thompson said that while the legislation is supported in concept by both Democrats and Republicans, it hasn’t won widespread reform, not piecemeal, and Republicans resist any reform until issues at the border are resolved.

“A lot of the holdup is really around this idea of upending the system,” Mr. Boswell said, “That’s where a lot of the pushback from other organizations comes from. You just keep at it.”

SHM CONVERGE

Rachel Thompson
Mr. Boswell

References


2. Weiner S. 1 in 5 U.S. physicians was born and educated abroad. Who are they and what do they contribute? Association of American Medical Colleges. 2023. https://www.aamc.org/news/1-5-us-physicians-was-born-and-educated-abroad-who-are-they-and-what-do-they-contribute?—text=Consider%20the%20statistics%3A%201%20in%202021%2C%20approximately%201 in%202020%2C more%20than%20one%20in%205%20of%20physicians%20are%20from

The Promotion Application Journey

Tips from a recently promoted professor

By Avital O’Glasser, MD, FACP, SFHM

Earlier this year, I was thrilled and honored to learn that my application for promotion to a full professor of medicine was approved. Any promotion in academic medicine is an accomplishment, and the broader context of my promotion made the milestone all the more special—I was days away from turning 42, mother to two school-aged children, and three years into the global pandemic, and I had an application packet heavy in non-traditional and digital scholarship, including advocacy work.

In the spirit of paying it forward, I want to share my reflection on the promotion-application journey and how I articulated my non-traditional scholarship in my application packet in a Tweetorial (https://twitter.com/aoglasser/status/167707532104371712), and now this article.

Global tips

The promotion journey, both the application process itself and the years of professional development and accomplishments leading up to it, can be lonely and stressful. Having a deep bench of mentors, sponsors, allies, and coaches was essential for me in the years leading up to the promotion and the application process itself. Having peer mentors and friends going through the process simultaneously was also invaluable for having logistical and emotional support. These types of relationships should be sought and nurtured regardless of one’s promotion plans or timeline. Having long-standing relationships that you can count on as part of your ongoing mentorship network will depend not only on your list of accomplishments but also on the impact and trajectory of your work, passions, and energies. No one will be in a better position to articulate your trajectory and momentum than YOU! The personal statement is fraught with imposter syndrome. Knowing the systematic constraints that typify medical careers in the 2020s, but I assure you proactive CV management will reap benefits, including time management and efficient data collection. I moved my CV and professional-dossier documents to the cloud several years ago and can update my CV from multiple devices. I add publications, talks, and other accomplishments to my CV as close to in real-time as possible to avoid the challenges of recall.

Make your professional dossier living, breathing documents as much as possible. Using cloud-based documents also creates the opportunity to leverage electronic documents in your professional dossier. Empower any reader of your CV and professional dossier to read between the lines of the item entered there. I include hyperlinks to everything from peer-reviewed and non-peer-reviewed work, blogs or op-eds, social-media-based teaching, and social-media-based advocacy, as well as metrics of impact and reach, such as Altmetric scores or media coverage of my research.

In addition to curating your CV and other components of the professional dossier, I highly recommend having a professional development or accomplishment rainy-day folder. Akin to the folder of thank-you cards from patients or trainees, at the very least a rainy-day folder (e.g., screenshots of positive feedback) can be the boost you need on a tough day. Additionally, it serves as a central repository for demonstrative feedback about your professional impact and reach, which is exactly what you need to supply in a promotion application. The rainy-day folder is also a great location to store and save the “I did this but don’t know how or where to put it on my CV” items.

Micro-technical tips

Eventually your evaluation for promotion (or other opportunities such as a new position or award) will depend not only on your list of accomplishments but also on the impact and trajectory of your work, passions, and energies. No one will be in a better position to articulate your trajectory and momentum than YOU! No one will be in a better position to articulate the challenges you’ve overcome and the difference you’ve made than YOU! The personal statement or cover letter is how to bring all the foundational tips I’ve shared thus far into the most impactful narrative of you as a clinician as possible.

Reference


For my promotion application, I had five pages maximum to tell my readers things that perhaps only I knew about my impact and trajectory. I used part of that valuable real estate to briefly highlight the data regarding pandemic-related gender inequities and non-promotable activities, the definition of digital scholarship, and the concept of the scholarship of engagement. I hope everyone has the psychologically safe space to call out the disruptions their professional trajectories have faced in recent years.

Remember that rainy daily folder? Review it and incorporate the highest-yield elements of feedback and proof of impact as much as possible. In addition to traditional evaluations (e.g., teaching evaluations, and CME lecture feedback), many means of feedback might occur via social media. I embedded select Twitter-based forms of feedback directly into my personal statement.

Any process that uses the professional dossier—job applications, annual reviews, award nominations, and promotion—is stressful. Find a way to talk about your work and your impact in a way that feels best and of the highest yield to you. Building on a foundation of mentorship relationships, I hope you feel empowered to fold traditional and non-traditional frameworks into any process that requires you to articulate your impact and reach as a hospitalist.
SIG Spotlight: Academic Leaders

By Richard Quinn

Ev very academic hospital medicine leader has two bosses: one on the academic side, through the school of medicine, and one on the hospital side, often reporting to someone in the C-suite, given its financial support of the program. Unfortunately, the priorities of the two bosses aren’t always aligned.

So how to best navigate multiple masters? How to learn how best to satisfy clinical, educational, and scholarly activities?

Well, clearly by joining SHM’s Academic Leaders Special Interest Group (SIG).

“Everyone is doing innovation in their own small silos or niche areas, and we just wanted to create a network where we are all talking to each other, bringing out the problems, solving as a group,” said SIG chair Romil Chadha, MD, MPH, MBA, SFHM.

“Whether we’re initiating a non-resident service, or justifying our subsidies to a hospital when they come into question, APP structure, leadership structure, or having residency challenges and needing to redesign the resident teams, what we’ve found is a lack of a centralized forum for people to learn from each other,” said vice chair Kendall Rogers, MD, CPE, SFHM. “We really saw the need for having academic leaders to have this forum to discuss these complex issues.”

Drs. Chadha and Rogers see the SIG as a repository of “social proofing,” where hospitalists and others associated with hospital medicine can learn novel solutions to problems they are facing, or just be validated by learning that their solutions have worked elsewhere. Dr. Chadha, chief medical information officer of the University of Kentucky Healthcare in Lexington, Ky, and prior chief of its division of hospital medicine said, “No one has found all the solutions, and that’s why we are here to work together to advance our specialty.”

“Similar to other programs, my institution values when I can refer to other institutions who have proven a certain way of doing things,” said Dr. Rogers, chief of the division of hospital medicine and professor at the University of New Mexico Health Sciences Center in Albuquerque, N.M. “Even if it’s the same thing that I’ve been advocating for, showing examples from other respected institutions, approaching a certain problem a certain way gives that external authority to help with local negotiations.”

“For a lot of us, we don’t even realize the problems we’ve already solved,” Dr. Rogers said. “It’s only when we hear someone else struggling with something that we realize a strength we have at our local environment, some process, some staffing aspect that we’ve already solved and now take for granted. So, we all have something we can learn from each other because we’re at different stages and settings.”

Dr. Rogers has hoped for years to develop a peer-mentoring program. That initiative—which he hopes will generate grassroots support—could include traveling to sites where national leaders work, or paying for them to travel to other institutions.

“It’s my hope to figure out a way to create a peer-exchange program where a new division or section chief can have a more experienced leader come in and visit their program and offer direct advice and mentorship,” he said. “There’s only so much you can do through Zoom or someone reporting to you what their program’s like. I’ve found seeing things first-hand is a whole exponentially higher in the content delivery and the information exchange that can occur. In addition, I have found that the person visiting gains as much from the experience as they deliver.”

Dr. Chadha wants as many high-level leaders in the SIG as possible, but he doesn’t draw the membership line at senior staffers only. “We do view it as a must for the academic division chiefs and it is strongly encouraged for next-reporting lines,” he said. “Everyone who reports to the division chief should be there. But, at the same time, I didn’t know what hospital medicine would be like unless I saw some mentors or looked at it closely.

“A medical student goes through many experiences before they decide what they want to practice. So, similarly, it is a good opportunity for people to see what working as a division chief or academic leader at an academic center for hospital medicine would look like. If you like it, you stay. If you don’t like it, you move on.”

Drs. Chadha and Rogers also note that for early-career physicians and others, joining the Academic Leaders SIG could be their first chance to step back from their daily work to see how pieces work more systematically.

“This may be one of the first times when people start to see how metrics or an organization works, where there are dotted lines and many people are different,” Dr. Chadha said. “That’s when reading the room, the art of negotiation, bringing the common interests together, how can that happen, all those things become extremely important…they can create these connections, they can find those mentors, they can learn from the repository and conversations. We hope more leaders join this resource, as we have so much to learn from each other.”

Richard Quinn is a freelance writer in New Jersey.
Chapter Spotlight: Central and Southwest Virginia

By Richard Quinn

S

hyam Odeti, MD, MS, FAAFP, MBA, SFHM, was in Johnson City, Tenn., five years or so ago when he helped start up an SHM chapter in the Blue Ridge Mountains of Tennessee and Virginia. He recalls the hours it took to recruit executive board members and the effort it took to wrangle and schedule event speakers. He knows all too well the time it takes away from other things, and the support it requires from so many for it to be a success.

So of course, he helped start up another one.

And that’s how the Central and Southwest Virginia Chapter started this year.

“Proximity is important,” said Dr. Odeti, section chief of Carilion Clinic in Roanoke, Va. “It has to be local enough that people can socialize. I cannot join the chapter in, say, Norfolk or Northern Virginia, or a chapter in Maryland or Tennessee. The focus is on forming a local community that allows face-to-face interactions, fosters connections, and facilitates gatherings amidst the busy schedules of hospitalist work.”

Dr. Odeti, an ardent advocate of the value of communal professional development and networking, views chapter gatherings less as work and more as a meet-up.

“It’s akin to reconnecting with a high-school friend,” he said. “You discover a plethora of shared interests and challenges. We aim to establish a chapter that provides a platform for sharing these common experiences, finding collective solutions, and fostering camaraderie through mutual understanding and support.”

As in many states with large swaths of rural areas, Central and Southwest Virginia have unique traits, but they also share socioeconomic problems and geographies peppered with mountains and valleys.

To Dr. Odeti, commonalities always outweigh differences.

Take payer mix, for example. Dr. Odeti says that across Virginia, about two-thirds of the population has private insurance, which usually indicates a much more affluent community, with good resources and also better reimbursement for hospitals.

“But, when you come to Central and Southwest Virginia, it’s opposite,” Dr. Odeti said. “About 60% of our patients have Medicare and Medicaid, and less than 40% have private insurance. Again, it speaks to the similarities of socioeconomic status of this region, the disparity with other regions of the state, and the distinct challenges we are dealing with.”

Dr. Odeti wants the chapter to grow quickly, but organically. He’s hoping to have at least one quarterly event and to have events between different geographic regions to facilitate local member engagement and provide a virtual option for others who can’t travel. He’s hopeful to tailor educational topics to those suggested by members—as the key to a successful chapter is engaged rank-and-file, not an enthusiastic chapter founder.

“What will keep them engaged is the value SHM and this chapter brings them and what happens at these meetings,” he said. “It’s fun, just like meeting your high-school friends or extended family, because you find a community when you come to these meetings. You learn from one another, and you will be able to take something back to where you work and improve the care for the patients you serve. With personal engagement, members will have opportunities for professional and leadership growth.”

One advantage of starting a chapter from scratch is that it makes it easier to pitch membership to anyone in the hospital medicine sphere, not only front-line doctors. That’s a little easier in a region with four medical schools.

“We have a breeding ground of future hospitalists,” Dr. Odeti said. “We have multiple physician assistant and nurse practitioner schools in the area, and we plan to invite them. Same thing with the residency programs. The ultimate goal is to welcome all individuals associated with hospital medicine, both clinically and non-clinically, whether currently involved or aspiring to join this field in the future.”

Dr. Odeti says he realizes that starting a chapter in a post-COVID-19 world could seem to some to be ill-timed. He flips that perspective and thinks of it as starting an in-person group at a time when hospitalists—and society at large—realize the value of face-to-face interactions.

“The first meeting we had was on July 21,” Dr. Odeti said. “And we had about 50 attendees turn out. And we had members joining from Charlo terville, which is about a two-and-a-half-hour drive. We also had hospitalists from Augusta, Blacksburg, and Radford, driving from a good distance to attend the evening meeting, and it was a great gathering. Everybody loved it. And Eric Howell was part of it, the CEO of SHM.

“Even though people work in different organizations, it feels like you are part of a larger family. We saw attendees sharing ideas about starting a new hospitalist fellowship program, not to recruit. In some discussions, we might not have found solutions, but at least we are not alone.’

At the chapter’s inaugural meeting, several seasoned hospitalists from community hospitals met folks they’ve transferred patients to for years.

“They never had the opportunity to collaborate or see people face-to-face,” Dr. Odeti said. “Hospitalists were thanking their counterparts for taking care of patients, but they never had the chance to interact or mingle. I see a bright future for this chapter.”

Richard Quinn is a freelance writer in New Jersey.
Join Our Award-Winning Team in Chattanooga, TN.

CHI Memorial Medical Group in Chattanooga, TN, is expanding our hospital medicine team. Nocturnists and hospitalists who enjoy managing complex adult patients with a full spectrum of specialty support are encouraged to join our team. CHI Memorial is a not-for-profit, faith-based, award-winning healthcare organization.

For More Information
Contact Alysia Smith at (615) 203-4959 or alysia.smith@commonspirit.org.

Salary and Benefits
- Fixed base plus production compensation
- 7-on/7-off schedule
- Sign-on bonus
- Relocation reimbursement
- Full benefits eligibility, including 401(k)
- CME, professional dues, licensure allowance, malpractice insurance
- Tennessee is an income tax free state

Education, Training, and Experience
- MD or DO
- Board certified/board eligible
- Ability to obtain an active medical license in Tennessee

CHI Memorial Medical Group

Medical Director Hospital Medicine
Beth Israel Deaconess - Milton
(Near Boston, MA)

Beth Israel Deaconess in Milton (bidmilton.org) is a leading regional community hospital providing nationally-recognized quality of care and patient safety while serving the greater Boston area. We are seeking a highly-motivated and collaborative Director of the Hospital Medicine department to lead and mentor the hospitalist team, oversee the day-to-day operations, and work closely with the hospital on various improvement initiatives, among other responsibilities. Applicants must be board-certified in Internal Medicine, have a minimum of 5 years of clinical, administrative and leadership experience.

If you are interested or want to learn more, please send your CV to:
Dr. Joseph Li, Chief of Hospital Medicine
jli2@bidmc.harvard.edu

and

Dr. Rusty Phillips, Director of Physician Recruitment
wphilip@bidmc.harvard.edu

Come join our team of Hospitalists!
(day and night, teaching and non-teaching opportunities)

Harvard Medical Faculty Physicians at Beth Israel Deaconess Medical Center - Boston, MA

The Hospital Medicine team at Beth Israel Deaconess is seeking Physicians for day and night, teaching and non-teaching opportunities at its Harvard-affiliated teaching hospital in Boston and at community hospitals in Milton, Needham and Plymouth. A medical school faculty appointment (Lecturer or Instructor in Medicine-full or part time) may also be possible. To learn more or apply, please contact Dr. Li or Dr. Phillips below.

Joseph Li, MD - Chief of Hospital Medicine
jli2@bidmc.harvard.edu

and

Rusty Phillips, MD - Director of Recruitment
wphilip@bidmc.harvard.edu

Additionally, by scanning this QR Code, you can download a comprehensive PDF brochure with an in-depth overview our hospital medicine service line.

We are an equal opportunity employer and all qualified applicants will receive consideration for employment without regard to race, color, religion, sex, national origin, disability status, protected veteran status, gender identity, sexual orientation, pregnancy and pregnancy-related conditions or any other characteristic protected by law.
THE OPPORTUNITIES

Join our collegial teams in Kamloops, Kelowna, Trail, and Vernon across the Southern Interior of beautiful British Columbia, Canada. Explore your passions in one of our stunning communities and experience first-hand what makes Interior Health a consistent recipient of the British Columbia Top 100 Employer award. In our breathtaking region, you'll find a harmonious blend of award-winning wineries, prestigious golf courses, world-class alpine resorts, and pristine lakes. Embrace the thrill of rugged mountain biking networks carved into the towering mountains and indulge in countless outdoor adventures. There is no doubt about it - it's better here.

Locum opportunities available!

INTERIOR HEALTH

Interior Health is committed to providing exceptional healthcare services to the communities and individuals in the Southern Interior of British Columbia. Our mission is to set new standards of excellence in healthcare delivery across the province. Our aim is to cultivate a supportive environment where you find fulfillment in your work, your workplace, and the people you work with. Each person's contribution is vital in ensuring seamless care, and together, we build thriving workplaces.